Clinical Trials

HSV1716: A Phase I Dose Escalation Study of Intratumoral Herpes Simplex Virus-1 Mutant HSV1716 In Patients with Refractory Non-Central Nervous System (Non-CNS) Solid Tumors/ Therapy for Relapse

What is the purpose of this study?

Primary
To determine whether intratumoral injection of HSV1716, at dose levels shown to be safe for adult tumors, is safe in adolescents and young adults with non-CNS solid tumors.

Time Frame: Dose limiting toxicities will be assessed at 28 days after injection of HSV1716.

Secondary
To measure antiviral immune response in patients with refractory cancer treated with HSV1716.

Time Frame: Antiviral immune response will be assessed 28 days after injection. Beginning at 1.5 years post injection, assessments will occur every 6 months. Beginning 5 years after the injection, assessments will occur annually until 15 years post injection.

Conditions

  • Cancer - Kidney Tumors
  • Cancer - Liver Tumors
  • Vaccines

Who should I contact for more information?

Laura Mayer, MS CCRP
Division of Hematology/Oncology
Cincinnati Children’s Hospital Medical Center
Laura.Mayer@cchmc.org
513-636-9419

Where can I find additional information?

Principal Investigator

Timothy P. Cripe, MD, PhD Professor of Pediatrics
Division of Hematology/Oncology Cincinnati Children’s Hospital Medical Center timothy.cripe@cchmc.org
513-636-4171